Background: Epidermal growth factor receptor (EGFR) mutations are frequently found in non-small cell lung cancer (NSCLC) patients. Various EGFR mutations respond differently to EGFR tyrosine kinase inhibitors (TKIs), and several TKIs have been
Search Results
HSR19-082: Epidemiological Findings and Outcomes in Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations: A Meta-Analysis
Victoria Crossland, Aaron Galaznik, Huamao M. Lin, Dimitrios Tomaras, Shan Ashton Garib, Shuanglian Li, Hui Huang, and Anna Forsythe
Carcinoma of Unknown Primary: Focused Evaluation
Gauri R. Varadhachary
: EGFR, epidermal growth factor receptor; IHC, immunohistochemistry. Several groups have studied the role of immunohistochemistry patterns and decision trees based on immunohistochemistry specificity, sensitivity, and predictive values. These data
Sequencing of Treatment in Advanced Unresectable Colorectal Cancer
Jean L. Grem
status in a Clinical Laboratory Improvement Amendments (CLIA)-accredited laboratory. 12 Retrospective analysis indicates that patients with mutations in the KRAS gene do not benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy
Advances in the Treatment of Non-Small Cell Lung Cancer
Leora Horn
information, revealing whether the tumor is negative for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations, for instance. Histology guides treatment choices, and clinical trial data tend to support this approach. For
Biomarker-Based Treatment Selection in Non–Small Cell Lung Cancer
Wallace Akerley
circumventing the immune system. Molecular markers such as epidermal growth factor receptor ( EGFR ), anaplastic lymphoma kinase ( ALK ), and ROS1 are now required in the 2017 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for testing in stage
The Role of Inhibitors of the Epidermal Growth Factor in Management of Head and Neck Cancer
Bruce Brockstein, Mario Lacouture, and Mark Agulnik
Edited by Kerrin G. Robinson
. Yarden Y . The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities . Eur J Cancer 2001 ; 37 ( Suppl 4 ): S3 – 8 . 17. Schlessinger J . Cell signaling by receptor tyrosine kinases . Cell 2000
Targeted Therapy for Metastatic Non–Small Cell Lung Cancer
Presented by: Gregory J. Riely
. “There are multiple molecular targets with agents approved for use in the first-line setting, including EGFR , ALK , ROS1 , RET , MET exon 14, and BRAF mutations. Targeted therapies are addressing targets that we’ve not been able to target before
Ten Years of Progress in Colon Cancer Therapy
Paul F. Engstrom
antibody to epidermal growth factor (EGFR), were introduced as single agents in the management of patients with advanced metastatic disease. Randomized studies showed that treatment with at least 3 of these agents could result in higher antitumor response
Volume 19 (2021): Issue Suppl_2 (Dec 2021): Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations
- Dec 2021
New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer
Presented by: Gregory J. Riely
options. It is well known that the most common biomarker is PD-L1 status, which is categorized as negative, low (1%–49%), or high (≥50%). NSCLC is also classified by mutations and gene fusions, with EGFR -sensitizing mutations being the most common. For
